Soft tissue sarcomas

Ca-A Cancer Journal for Clinicians

Volumn 54, Issue 2, 2004, Pages 94-109

  Cormier, Janice N ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; PROTEIN C MYB; PROTEIN MDM2; RAS PROTEIN; STEM CELL FACTOR;

BONE MARROW TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRACTURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; EDEMA; FIBROSIS; FOOT PAIN; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MESODERM; METASTASIS POTENTIAL; NECROSIS; NEEDLE BIOPSY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROPERITONEAL CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TRUNK; TUMOR BIOPSY; TUMOR VOLUME;

EID: 1942536503     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.54.2.94     Document Type: Review

References (122)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1841-1891.
3. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
4. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993;217:72-77.
5. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:1379.
6. Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24: 504-514.
7. Hardell L, Sandstron A. A case-control study: soft tissue sarcoma and exposure to phenoxyacetic acids or chlorophenols. Br J Cancer 1979;39: 711-717.
8. Smith AH, Pearce NE, Fisher DO. Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. J Nat Cancer Inst 1984;73:1111.
9. Muller R, Hajdu SI, Brennan MF. Lymphangiosarcoma associated with chronic filarial lymphedema. Cancer 1987;59:179.
10. Levine EA. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999;17.
11. Vorburger SA, Hunt KK. Experimental Approaches, in Pollock RE (ed). Soft Tissue Sarcomas. Hamilton, Ontario, BC Decker, Inc., 2002:89-109.
12. Latres E, Drobnjak M, Pollack D, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994;145: 345-355.
13. Hieken TJ, Das Gupta TK. Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma. Clin Cancer Res 1996;2:1391-1395.
14. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am 1999;8: 91-107.
15. Pearlstone DB, Pisters PW, Bold RJ, et al. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 1999;85:85-92.
16. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629-650.
17. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988; 50:615-620.
18. de Saint Aubain Somerhausen N, Fletcher CD. Soft-tissue sarcomas: an update. Eur J Surg Oncol 1999;25:215-220.
19. Dupuy DE, Rosenberg AE, Punyaratabandhu T, et al. Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms. AJR Am J Roentgenol 1998;171:759-762.
20. Greene FL, Page DL, Fleming FD, et al. (eds). American Joint Committee on Cancer: Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:221-226.
21. Singer S. New diagnostic modalities in soft tissue sarcoma. Semin Surg Oncol 1999;17: 11-22.
22. Shiraki M, Enterline HT, Brooks JJ, et al. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1989;64:484-490.
23. Presant CA, Russell WO, Alexander RW, et al. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. J Clin Oncol 1986;4:1658 -1661.
24. Alvegard TA, Berg NO. Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1989;7:1845-51.
25. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869-877.
26. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984;53:530-541.
27. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
28. Ramanathan RC, A'Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol 1999;6: 57-69.
29. Fleming ID, ed. American Joint Committee on Cancer: Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1998.
30. Putnam JB. Metastases from Sarcoma, in Pollock RE (ed). American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamiliton, Ontario: BC Decker, Inc.; 2002: 266-278.
31. Pisters P. Staging and Prognosis, in Pollock RE (ed). American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas. Hamiliton, Ontario: BC Decker, Inc.; 2002:80-88.
32. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-1689.
33. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
34. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69: 1334-1341.
35. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995;2:26-31.
36. National Institute of Health consensus development panel on limb-sparing treatment of adult soft tissue sarcoma and osteosarcomas. Proceedings of Cancer Treatment Symposium, 1985, pp 1-5.
37. Brennan MF, Casper ES, Harrison LB, et al. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 1991;214:328-36.
38. Herbert SH, Corn BW, Solin LJ, et al. Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins. Cancer 1993;72:1230-1238.
39. Tanabe KK, Pollock RE, Ellis LM, et al. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer 1994;73:1652-1659.
40. Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981;47:2391-2397.
41. Suit HD, Russell WO. Radiation therapy of soft tissue sarcomas. Cancer 1975;36:759-764.
42. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
43. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-868.
44. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 1994;10:347-356.
45. Barkley HT Jr., Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 1988;14: 693-699.
46. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
47. Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994;219:165-173.
48. Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987;5:601-612.
49. Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127: 1285-1289.
50. Karakousis CP, Emrich LJ, Rao U, Khalil M. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol 1991;17:71-80.
51. Suit HD, Mankin HJ, Wood WC, Proppe KH. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 1985;55:2659-2667.
52. Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230.
53. Nielsen OS, Cummings B, O'Sullivan B, et al. Preoperative and postoperative irradiation of soft tissue sarcomas: effect of radiation field size. Int J Radiat Oncol Biol Phys 1991;21: 1595-1599.
54. Bujko K, Suit HD, Springfield DS, Convery K. Wound healing after preoperative radiation for sarcoma of soft tissues. Surg Gynecol Obstet 1993;176:124-134.
55. Peat BG, Bell RS, Davis A, et al. Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg 1994;93:980-987.
56. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol 1996;61:90-99.
57. Prosnitz LR, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 1999;45:941-949.
58. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-2241.
59. Janjan NA, Yasko AW, Reece GP, et al. Comparison of charges related to radiotherapy for soft-tissue sarcomas treated by preoperative external-beam irradiation versus interstitial implantation. Ann Surg Oncol 1994;1:415-422.
60. Wylie JP, O'Sullivan B, Carton C, Gutierrez E. Contemporary radiotherapy for soft tissue sarcoma. Semin Surg Oncol 1999;17:33-46.
61. Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1991;21:1493-1499.
62. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
63. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000;36:61-67.
64. Frustaci S, Buonadonna A, Romanini A, et al. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Tumori 1999;85:229-233.
65. Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol 1997;8:1159-1162.
66. Buesa JM, Lopez-Pousa A, Martin J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998;9:871-876.
67. Demetri GD. Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr Opin Oncol 1998;10: 343-347.
68. Tierney JF. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
69. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
70. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002;25:468-473.
71. Brodowicz T, Schwameis E, Widder J. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma 2000;4:151-160.
72. Figueredo A, Bramwell VHC, Bell R, et al. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline. Sarcoma 2002;6:5-18.
73. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19:3203-3209.
74. Ottaiano, A, De Chiara A, Fazioli F, et al. Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: five-year results with epirubicin and ifosfamide. Anticancer Res 2002;22:3555-3559.
75. Henshaw RM, Priebat DA, Perry DJ, et al. Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol 2001;8: 484-495.
76. Rahoty P, Konya A. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol 1993;19:641-645.
77. Meric F, Hess KR, Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120-1126.
78. Eilber FR, Giuliano AE, Huth JH, et al. Neoadjuvant Chemotherapy, Radiation, and Limited Surgery for High Grade Soft Tissue Sarcoma of the Extremity, in Ryan JR, Baker LO (eds). Recent Concepts in Sarcoma Treatment. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1988:115-122.
79. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9:535-42.
80. Goodnight JE Jr., Bargar WL, Voegeh T, et al. Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg 1985;150:109-113.
81. Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer 1993;71:3685-3689.
82. Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995;75: 2299-2306.
83. Temple WJ, Temple CL, Arthur K, et al. Prospective cohort study of neoadjuvant treatment in conservative surgery ofsoft tissue sarcomas. Ann Surg Oncol 1997;4:586-590.
84. Rhomberg W, Hassenstein EO, Gefeller D. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 1996;36:1077-1084.
85. Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer 1991;67:572-576.
86. Sondak VK, Robertson JM, Sussman JJ. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann Surg Oncol 1998;5:106-112.
87. Pisters PW. Chemoradiation treatment strategies for localized sarcoma: conventional and investigational approaches. Semin Surg Oncol 1999;17:66-71.
88. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology 1994;190:263-268.
89. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355-365.
90. Catton CN, O'Sullivan B, Kotwall C, et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29:1005-1010.
91. Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990;212:51-59.
92. Pisters PW, O'Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol 2002;14:400-405.
93. Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol 2002;9:346-354.
94. Petersen IA, Haddock MG, Donohue JH, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2002;52:469-475.
95. Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2001;50:127-131.
96. Grant CS, Kim CH, Farrugia G, et al. Gastric leiomyosarcoma. Prognostic factors and surgical management. Arch Surg 1991;126:985-989.
97. Carson W, Karakousis C, Douglass H, et al. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol 1994;1:244-251.
98. Shiu MH, Farr GH, Egeli RA, et al. Myosarcomas of the small and large intestine: a clinicopathologic study. J Surg Oncol 1983;24:67-72.
99. McGrath PC, Neifeld JP, Lawrence W Jr., et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987;206:706-710.
100. Lindsay PC, Ordonez N, Raaf JH. Gastric leiomyosarcoma: clinical and pathological review of fifty patients. J Surg Oncol 1981;18:399-421.
101. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152: 1259-1269.
102. Chan JK. Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP. GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol 1999;6:19-40.
103. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal rumors. Science 1998; 279:577-580.
104. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11: 728-734.
105. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220.
106. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-4300.
107. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-224.
108. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345-1364.
109. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
110. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit protooncogene. Cell 1990;63:167-174.
111. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
112. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
113. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
114. von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002;abstract 1608.
115. Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol 1999; 17:83-87.
116. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3: 353-366.
117. Nori D, Schupak K, Shiu MH, et al. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys 1991;20: 1229-1233.
118. Midis GP, Pollock RE, Chen NP, et al. Locally recurrent soft tissue sarcoma of the extremities. Surgery 1998;123:666-671.
119. Karakousis CP, Proimakis C, Rao U, et al. Local recurrence and survival in soft-tissue sarcomas. Ann Surg Oncol 1996;3:255-260.
120. Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548-553.
121. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 1996;77:675-682.
122. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-157.